Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381279763> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W4381279763 abstract "Abstract Background Anti-PD-1/L1 antibody + anti-VEGF antibody (A + A) and anti-PD-1/L1 antibody + VEGFR-targeted tyrosine kinase inhibitor (A + T) are both effective first-line therapies for uHCC. However, direct comparisons between them are not available. We conducted a network meta-analysis of them in terms of overall survival (OS), progression free survival (PFS), objective response rate (ORR) and incidence of treatment-related adverse events (TRAEs). Methods After a rigorous literature research, 6 phase III trials has been identified for the final analysis: IMbrave150, ORIENT-32, COSMIC-312, CARES-310, LEAP-002 and REFLECT. The experiments were classified into three groups: A + A, A + T and intermediate reference group. We derived hazard ratios (HR) with 95% confidence intervals (95%CI) for OS and PFS, odds ratio (OR) for ORR and relative risks (RR) for all grade and ≥ 3 TRAEs. With fixed effect models to estimate the indirect pooled HRs, ORs, RRs and 95%CI, a frequentist network meta-analysis was conducted using sorafenib as intermediate reference. Results With a P-score of 98%, A + A provided the greatest reduction in the risk of death, without significant difference from A + T (HR = 0.84, 95%CI: 0.66–1.06). Besides, A + T showed the greatest effect in prolonging PFS and improving ORR with 91% for P-score, but there are no statistical differences with A + A(HR = 1.06, 95%CI: 0.87–1.30, OR = 0.82, 95%CI: 0.47–1.46). A + A were significantly safer than A + T (RR = 0.91, 95%CI: 0.84–0.98) in all grade of TRAEs and ≥ 3 (RR = 0.91, 95%CI: 0.84–0.98). Conclusions A + A has the greatest probability of delivering the longest OS, while A + T is correlated with larger PFS benefit at the cost of a lower safety rate." @default.
- W4381279763 created "2023-06-21" @default.
- W4381279763 creator A5018758754 @default.
- W4381279763 creator A5029435040 @default.
- W4381279763 creator A5035636564 @default.
- W4381279763 creator A5060655025 @default.
- W4381279763 creator A5064704774 @default.
- W4381279763 date "2023-05-30" @default.
- W4381279763 modified "2023-09-27" @default.
- W4381279763 title "Comparative efficacy and safety of anti-PD-1/L1 antibody plus anti-VEGF antibody and anti-PD-1/L1 antibody plus VEGFR-targeted tyrosine kinase inhibitor as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a systematic review and network meta- analysis" @default.
- W4381279763 cites W1487455823 @default.
- W4381279763 cites W1971837077 @default.
- W4381279763 cites W1994193851 @default.
- W4381279763 cites W2787358630 @default.
- W4381279763 cites W2791328450 @default.
- W4381279763 cites W2910126224 @default.
- W4381279763 cites W2965242861 @default.
- W4381279763 cites W3000074215 @default.
- W4381279763 cites W3030165187 @default.
- W4381279763 cites W3048739245 @default.
- W4381279763 cites W3128646645 @default.
- W4381279763 cites W3129833353 @default.
- W4381279763 cites W3147142721 @default.
- W4381279763 cites W3149900842 @default.
- W4381279763 cites W3165241302 @default.
- W4381279763 cites W3166753505 @default.
- W4381279763 cites W3174077356 @default.
- W4381279763 cites W3208308450 @default.
- W4381279763 cites W4200354524 @default.
- W4381279763 cites W4200388794 @default.
- W4381279763 cites W4220868030 @default.
- W4381279763 cites W4223510226 @default.
- W4381279763 cites W4223628857 @default.
- W4381279763 cites W4226360696 @default.
- W4381279763 cites W4283812631 @default.
- W4381279763 cites W4297986221 @default.
- W4381279763 cites W4306404153 @default.
- W4381279763 cites W4310862521 @default.
- W4381279763 cites W4313646349 @default.
- W4381279763 cites W4313825824 @default.
- W4381279763 cites W4315650243 @default.
- W4381279763 cites W4317721816 @default.
- W4381279763 cites W4319000849 @default.
- W4381279763 cites W4322772603 @default.
- W4381279763 cites W4323043935 @default.
- W4381279763 doi "https://doi.org/10.21203/rs.3.rs-2961338/v1" @default.
- W4381279763 hasPublicationYear "2023" @default.
- W4381279763 type Work @default.
- W4381279763 citedByCount "0" @default.
- W4381279763 crossrefType "posted-content" @default.
- W4381279763 hasAuthorship W4381279763A5018758754 @default.
- W4381279763 hasAuthorship W4381279763A5029435040 @default.
- W4381279763 hasAuthorship W4381279763A5035636564 @default.
- W4381279763 hasAuthorship W4381279763A5060655025 @default.
- W4381279763 hasAuthorship W4381279763A5064704774 @default.
- W4381279763 hasBestOaLocation W43812797631 @default.
- W4381279763 hasConcept C126322002 @default.
- W4381279763 hasConcept C143998085 @default.
- W4381279763 hasConcept C159654299 @default.
- W4381279763 hasConcept C197934379 @default.
- W4381279763 hasConcept C203014093 @default.
- W4381279763 hasConcept C207103383 @default.
- W4381279763 hasConcept C44249647 @default.
- W4381279763 hasConcept C71924100 @default.
- W4381279763 hasConcept C82789193 @default.
- W4381279763 hasConceptScore W4381279763C126322002 @default.
- W4381279763 hasConceptScore W4381279763C143998085 @default.
- W4381279763 hasConceptScore W4381279763C159654299 @default.
- W4381279763 hasConceptScore W4381279763C197934379 @default.
- W4381279763 hasConceptScore W4381279763C203014093 @default.
- W4381279763 hasConceptScore W4381279763C207103383 @default.
- W4381279763 hasConceptScore W4381279763C44249647 @default.
- W4381279763 hasConceptScore W4381279763C71924100 @default.
- W4381279763 hasConceptScore W4381279763C82789193 @default.
- W4381279763 hasLocation W43812797631 @default.
- W4381279763 hasOpenAccess W4381279763 @default.
- W4381279763 hasPrimaryLocation W43812797631 @default.
- W4381279763 hasRelatedWork W1900595920 @default.
- W4381279763 hasRelatedWork W2109001439 @default.
- W4381279763 hasRelatedWork W2114624491 @default.
- W4381279763 hasRelatedWork W2154948599 @default.
- W4381279763 hasRelatedWork W2194631636 @default.
- W4381279763 hasRelatedWork W2793335702 @default.
- W4381279763 hasRelatedWork W2889691785 @default.
- W4381279763 hasRelatedWork W2894284291 @default.
- W4381279763 hasRelatedWork W4210646467 @default.
- W4381279763 hasRelatedWork W4386760128 @default.
- W4381279763 isParatext "false" @default.
- W4381279763 isRetracted "false" @default.
- W4381279763 workType "article" @default.